Is HIMS stock a Buy, Sell, or Hold?

Based on our analysis, HIMS is currently a HOLD with moderate confidence. 📊 HOLD: HIMS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of HIMS stock?

Our analysis estimates the fair value range for HIMS to be between $29.81 and $34.37. The current price is $27.09.

What is the analyst price target for HIMS?

The average Wall Street analyst price target for HIMS is $41.62. This implies a potential upside of 53.6% from current levels.

HIMS Stock Analysis: Buy, Sell, or Hold?

HIMS - Hims & Hers Health, Inc.

SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE

$27.09

-2.78 (-9.31%) ▼

HOLD

MODERATE Confidence

Protect Your HIMS Gains

Last Updated: January 30, 2026

Earnings: Feb 23, 2026 21d

Get Alerted When HIMS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: HIMS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$30.55

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$18.97

Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: HIMS is currently trading at $27.09, which is considered oversold relative to its 30-day fair value range of $29.81 to $34.37. From a valuation perspective, the stock is trading at a discount (Forward PE: 43.2) compared to its historical average (52.4). Remarkably, the market is currently pricing in an annual earnings decline of 6.3% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, HIMS is in a strong downtrend. The price is currently testing key support at $26.87. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.3% recently.

Market Sentiment: HIMS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $41.62 (+53.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Fair Price Range $29.81 - $34.37

Company Quality Score 56/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 52.4%

Protect Your Profits

Holding HIMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
BEARISH: Downward momentum (-9.3%)
BULLISH: Trading 53.6% below Wall St target ($41.62)
CAUTION: 5-day price weakness (-8.5%) - monitor closely

Fair Price Analysis

30-Day Fair Range $29.81 - $34.37

Current vs Fair Value OVERSOLD

Support & Resistance Levels

Support Level $26.87

Resistance Level $31.82

Current Trend Strong Downtrend

Fundamental Context

Forward P/E (Next Year Est.) 43.16

Wall Street Target $41.62 (+53.6%)

Revenue Growth (YoY) 49.2%

Earnings Growth (YoY) -80.3%

Profit Margin 6.0%

Valuation Discount vs History -6.3% cheaper

PE vs Historical 43.2 vs 52.4 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -6.3% (market-implied from PE analysis)

1-Year Target $25.38 (-6%)

2-Year Target $23.78 (-12%)

3-Year Target $22.29 (-18%)

3-Yr Target (if PE normalizes) (PE: 43→52) $27.05 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 43.2, Growth: 30.9%) $60.78 (+124%)

Base: (SPY PE: 22.3, Growth: 30.9%) $31.40 (+16%)

Bear: (PE: 19.0, Growth: 30.9%) $26.69 (-2%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (54x PE), but valuation improves significantly next year (43x PE) as earnings recover.

Trailing PE: 54.09 | Current EPS (TTM): $0.53

Bull Case $37.34 (+38%)

Analyst growth 18.4%, PE expands to 59.5

Base Case $33.95 (+25%)

Market implied 18.4%, PE stable at 54.1

Bear Case $19.50 (-28%)

Severe decline -20.0%, PE contracts to 46.0

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 43.2 to 52.4

Stabilization Target: $32.89 (+21.4%)

PE Expansion Potential: +21.4%

Last updated: February 01, 2026 11:14 AM ET
Data refreshes hourly during market hours. Next update: 12:14 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is HIMS showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Oluyemi Okupe SELL 11592 shares 2025-10-17

Soleil Boughton SELL 2637 shares 2025-10-13

Michael Chi SELL 900 shares 2025-10-10

View Insider Activity Scanner

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
NBIX Neurocrine Biosciences I…	STRONG BUY 25 analysts	$180	62 BUY
ZTS Zoetis Inc	STRONG BUY 19 analysts	$154	56 HOLD
LNTH Lantheus Holdings Inc	STRONG BUY 13 analysts	$83	57 HOLD
BCRX BioCryst Pharmaceuticals…	STRONG BUY 12 analysts	$22	55 HOLD
HCM HUTCHMED DRC	STRONG BUY 14 analysts	$21	57 HOLD

NBIX Neurocrine Biosci…

62 BUY

ZTS Zoetis Inc

56 HOLD

LNTH Lantheus Holdings…

57 HOLD

BCRX BioCryst Pharmace…

55 HOLD

HCM HUTCHMED DRC

57 HOLD

Advanced HIMS Option Strategies

Professional options setups generated by AI based on today's HIMS price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for HIMS

HIMS Technical Chart HIMS Price Prediction HIMS Earnings Date HIMS Investment Advisor HIMS Fair Price Analyzer HIMS Options Advisor HIMS Options Chain HIMS Options Analysis HIMS Competitors

Compare HIMS with Other Stocks

HIMS vs IAU
Winner: HIMS

FUTU vs HIMS

HIMS vs UPS

Create New Comparison

Tradestie